Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden

Headache

Volumn 47, Issue 4, 2007, Pages 475-479

  Bigal, Marcelo ^a,b   Rapoport, Alan ^b   Aurora, Sheena ^c   Sheftell, Fred ^b   Tepper, Stewart ^b   Dahlof, Carl ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c Swedish Pain Center   (United States)

^d Migraine Clinic   (Sweden)

Author keywords

Migraine; Preference; Satisfaction; Treatment

Indexed keywords

SUMATRIPTAN; TRIPTAN DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; SCALE UP; TERTIARY HEALTH CARE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SUMATRIPTAN; SWEDEN; TIME FACTORS; TRYPTAMINES; UNITED STATES; VASOCONSTRICTOR AGENTS;

EID: 34247276003     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00752.x     Document Type: Article

References (19)

1. Dahlof C. Assessing patient preference in migraine treatment. Cephalalgia. 2001;21:791-795.
2. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: How to match patients and products. CNS Drugs. 2003;17:431-447.
3. Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: Prioritizing oral triptan treatment attributes in migraine management. Acta Neurol Scand. 2004;110:137-143.
4. Jadad AR, Rennie D. The randomized controlled trial gets a middle-aged checkup. JAMA. 1998;279:319-320.
5. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, doubledummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia. 1999;19:581-588.
6. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology. 2000;54:156-163.
7. Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia. 2003;23:942-952.
8. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44:661-668.
9. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24(suppl 1):9-160.
10. Dahlof C, Jones M, Davis K, Loftus J, Salonen R. A comparison of preference for and efficacy of tablet formulations of Sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), Rizatriptan (10 mg), and Zolmitriptan (2.5 mg) in the acute treatment of migraine. J Headache Pain. 2004;5:115-122.
11. Dahlof CG, Adolfsson LE, Lygner PE, et al. Acute migraine utilization in Sumatriptan users. Patterns of use in primary care vs. specialty care. Headache Care. 2005;2:163-170.
12. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - Current understanding and treatment. N Engl J Med. 2002;346:257-270.
13. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259-1287.
14. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol. 2001;58:1479-1480.
15. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
16. Dodick DW, Silberstein S, Dahlöf CGH. Is there a preferred triptan? [editorial]. Headache. 2002;42:1-7.
17. Evans RW, Dahlof CG. Determining triptan preference for the individual patient. Headache. 2004;44:723-725.
18. Sheftell FD, Feleppa M, Tepper SJ, Rapoport AM, Ciannella L, Bigal ME. Assessment of adverse events associated with triptans - Methods of assessment influence the results. Headache. 2004;44:978-982.
19. Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: A study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004;26:1533-1545.